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TIME TO CASTRATION RESISTANCE AND OUTCOMES FOLLOWING
DOCETAXEL CHEMOTHERAPY IN MEN WITH ADVANCED PROSTATE
CANCER
Philip Bredin1, Margaret Lee1, Phillip Parente1,2, Joseph McKendrick1,2,
Cristina Moldovan1, Ian Davis1,2, Carmel Pezaro1,2
1Eastern Health, Box Hill, VIC, Australia, 2Eastern Health Clinical School,
Monash University, Melbourne, VIC, Australia
Background: Patients with metastatic prostate cancer (MPC) eventually
progress to castration-resistant disease (CR-MPC) on androgen deprivation
therapy (ADT). Time to castration resistance (TTCR) has been associated
with duration of response to second-line androgen-receptor axis targeted
agents; however, the relationship to outcome with docetaxel chemotherapy
is less well-defined. We evaluated the relationship between first-line ADT, do-
cetaxel treatment and long-term outcomes.
Method: Medical records of patients with CR-MPC treated with docetaxel at
a tertiary hospital in Melbourne, Australia, were evaluated. Between January
2008 and December 2015, 70 eligible patients were identified. ADT duration
was defined as the period of castration (single-agent or combined with anti-
androgen) prior to initiation of docetaxel. TTCRwas defined as the time from
continuous ADT initiation to biochemical progression (castrate-resistance:
CR). Pre-chemotherapy CR therapy (CRCT) was defined as the time from
CR to docetaxel initiation. Overall survival (OS) by TTCR, CRCT, and ADT
duration was compared using log-rank tests.
Results: The patient cohort was similar to those reported in large popula-
tion studies. At docetaxel initiation, the median age was 73 years (range 54–
89), 89% of patients were ECOG 0–1, 87% had bone and 17% had visceral
metastases, respectively.
TTCR was analyzed in tertiles: T1 = 0.1–0.8 years (y); T2 = 0.8–1.7 y; T3
= 1.7–9.5 y. No significant difference in median OS was observed (T1 = 1.4
y, T2 = 2.2 y, T3 = 2.6 y; P = 0.17).
CRCT in tertiles was: T1= 0–0.3 y; T2= 0.3–1 y; T3= 1–8.7 y. This interval
strongly associated with median OS (T1 = 0.1 y vs T3 = 2 y, P = 0.0004).
ADT duration was: T1 = 0.3–1.2 y; T2 = 1.2–3 y; T3 = 3–15.7 y. Again,
a shorter interval before docetaxel was significantly associated with poorer
median OS (T1 = 1.2 y vs T3 = 2.6 y, P = 0.0007).
Conclusion: No association was observed between TTCR in tertiles and me-
dian OS. However, time from continuous ADT to docetaxel initiation and
CRCT both significantly associated with OS. ADT duration and CRCT are
simple intervals to calculate and appear worthy of further study.
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A COHORT STUDY OF DE NOVOMETASTATIC PROSTATE CANCER
FROM THE SOUTH AUSTRALIAN PROSTATE CANCER CLINICAL
OUTCOME COLLABORATIVE
Johan Chan1, G Kichenadasse2, M O’callagan3, S Walsh3, T Kopsaftis3, M
Borg4, K Moretti5
1RAH, ADELAIDE, SA, Australia, 2Department of Oncology, Flinders
Cancer Centre, Adelaide, SA, Australia, 3Department of Urology,
SA-PCCOC, Adelaide, SA, Australia, 4Radiation Oncologist, Adelaide
Radiotherapy Centre, Adelaide, SA, Australia, 5Department of Urology,
Queen Elizabeth Hospital, Adelaide, SA, Australia
The incidence of men with de novo metastatic prostate cancer (dnmPC)
has been reported to be 4–5% in several retrospective analysis from West-
ern countries.1,2 We recently performed a retrospective analysis of men with
prostate cancer using the South Australian Prostate Cancer Clinical Outcome
Collaborative (SA-PCCOC) database. A total of 7941 patients were included
in the analysis. The incidence of dnmPC was 3%, with 246 patients fulfill-
ing the inclusion criteria for the study. The incidence of dnmPC has dropped
from 1998–2005 (6.6%) to 2010 - 2015 (1.3%). The mean age at diagnosis
of men with dnmPC cohort was 73 years; 94 (38.2%) patients had prostate-
specific antigen (PSA) >20 on diagnosis whereas 118 (48%) patients had
Gleason score >7. This is in comparison to the remainder of the cohort where
(17.1%) had Gleason score >7 and 78% had Gleason score 7 on diagnosis
of prostate cancer. Diagnosis of prostate cancer was confirmed with transrec-
tal ultrasound guided biopsy in 62% whereas transurethral resection of the
prostate was performed in 21.5%. A large majority (70.3%) of patients had
hormonal deprivation therapy as the preferred treatment whereas 6.9% had
either surgery or radiotherapy. The mean overall survival for the men with dn-
mPC was 41.9 months compared to 75.7 months for those without recorded
metastases at diagnosis. Gleason score (P = 0.037) and use of local therapy
(P = 0.006) were associated with overall survival among those patients who
had metastases at the time of diagnosis.
Conclusion: The incidence of men with dnmPC is declining possibly due to
increased screening tests over the last two decades. The survival of dnmPC
cohort appears lower than those with advanced recurrent disease. Further
research is warranted to evaluate this uncommon cohort of men with dnmPC.
References
1. Characterization of patients who present with de novometastatic prostate
cancer: single-institution database analysis. J Clin Oncol 2013; 31 (Suppl
6): abstr 33.
2. Characterization of differences between prostate cancer (PCa) patients
presenting as de novo versus primary progressive metastatic disease. J Clin
Oncol 2015; 33 (Suppl 7): abstr 285.
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‘CHANGING LANES’: REAL-TIME CHEMOTHERAPY SWITCHING IN
ADVANCED PROSTATE CANCER
Rachel Delahunty1, CL Gan2, P Parente1, D Pook2,3, C Pezaro1
1Oncology, Eastern Health, Melbourne, Victoria, Australia, 2Oncology,
Monash Health, Melbourne, Victoria, Australia, 3Oncology, Cabrini Health,
Melbourne, Victoria, Australia
Background: Men with castration-resistant prostate cancer (CRPC) refrac-
tory to docetaxel are thought to have poor outcomes. The TROPIC study
demonstrated that patients progressing after docetaxel derive benefit from
cabazitaxel. However, the role of a real-time switch to cabazitaxel in patients
progressing whilst receiving docetaxel is unclear.We aimed to assess the safety
and activity of cabazitaxel switch in patients with CRPC.
Methods: On retrospective review we identified seven patients from two Vic-
torian centers.We collected patient demographics, prostate cancer history and
clinical outcomes on chemotherapy. Docetaxel-refractory disease was defined
as progression without prior evidence of response. Survival was calculated us-
ing the Kaplan Meier method.
Results: The median age of patients at commencement of docetaxel was
72 years (range 64–80). CRPC developed a median of 12.3 months (range
4.0–34.7) after initiation of androgen deprivation. Prior treatments included
enzalutamide (in three patients) and abiraterone (one patient). Five of the
patients had docetaxel-refractory disease. Patients received a median of 6
(range 2–10) docetaxel cycles and the median interval between last docetaxel
and cabazitaxel initiation was 28 days (range 22–49). The median number
of cabazitaxel cycles was 2 (range 2–10). Three patients had evidence of
prostate-specific antigen decline on treatment. Cabazitaxel toxicity was con-
sistent with phase III data: four patients reported adverse events, with one
episode of grade 3 febrile neutropenia requiring dose reduction. Four patients
ceased treatment due to progression and one due to declining performance
status. One patient died within 30 days of the last dose of cabazitaxel. The
median survival from commencing cabazitaxel was 6.5 months, with two pa-
tients still alive and receiving treatment.
Conclusions: In this case series of highly selected patients with pretreated
docetaxel-resistant CRPC, real-time switch to cabazitaxel did not cause un-
expected toxicity. Clinical outcomes were generally poor, however, with little
evidence to suggest reversal of chemotherapy resistance.
C© 2016 The Authors. Asia-Pacific Journal of Clinical Oncology Asia-Pac J Clin Oncol 2016; 12(Suppl. 3): 34–43
C© 2016 Wiley Publishing Asia Pty Ltd
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PREDICTORS OF FEBRILE NEUTROPAENIA AND EARLY TREATMENT
CESSATION DUE TO TOXICITY IN MEN RECEIVING Q3 WEEKLY
DOCETAXEL FOR METASTATIC CASTRATE RESISTANT PROSTATE
CANCER (MCRPC)
Anis Hamid1, K Wilson1, C Pezaro2, M Lee2, B Tran3, A Bergin3, C Gan3, B
Tamjid1, A Campbell1, J Stewart1, A Vincent4, A Weickhardt1
1Olivia Newton John Cancer Centre, Austin Hospital, Heidelberg, VIC,
Australia, 2Box Hill Hospital, Melbourne, Australia, 3Royal Melbourne
Hospital, Melbourne, Australia, 4Adelaide University, Adelaide, SA,
Australia
Background: Docetaxel is an effective therapy in metastatic castrate-resistant
prostate (mCRPC) cancer yet 20–40% of patients cease treatment early due
to toxicity. Baseline predictors of docetaxel toxicity in mCRPC are poorly
defined.
Method: An audit of 166 patients undergoing docetaxel chemotherapy for
mCRPC was undertaken at three hospitals. Baseline demographics were col-
lected including age, number of significant comorbidities (CCF, IHD, COPD,
CKD, or Dementia), ECOG status and starting dose of docetaxel (conven-
tional 75 mg/m2 vs low-dose defined as <60 mg/m2). Toxicity and efficacy
data were collected. Logistic and Cox regression models were used to predict
toxicity and efficacy.
Results: Twenty-five of 166 (15%) patients developed febrile neutropenia.
Patients treated with low-dose docetaxel (n = 48, 29%) had a nonsignificant
trend to lower incidence of febrile neutropenia (odds ratio [OR] 0.69; confi-
dence interval [CI], 0.32–1.47; P = 0.33), but there were no significant pre-
dictors of this complication on multivariate analysis. 35% of patients ceased
docetaxel due to toxicity. Significant predictors on multivariate analysis of
ceasing treatment early for toxicity were age (OR 1.5; CI, 1.1–2.0; P= 0.006)
and number of comorbidities (OR 1.4; CI, 1.2–1.6,P< 0.0001). LD docetaxel
was not associated with increased risk of treatment cessation for toxicity, yet
was associated with a significant reduction in PSA response (OR 0.54; CI,
0.31–0.93; P = 0.03), and significantly poorer overall survival (HR 2.19;
CI, 1.55–3.08; P < 0.0001) even adjusting for baseline covariates of poorer
health.
Summary: Age and number of comorbidities are significant predictors for
risk of ceasing docetaxel chemotherapy for toxicity in mCRPC. There is a
trend to lower incidence of febrile neutropenia in patients started on lower
dose chemotherapy but this approach does not significantly reduce the risk of
early treatment cessation for toxicity, and additionally appears to lower PSA
response rates and contributes to poorer overall survival.
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DEVELOPING A PERSONALIZED APPROACH TO PROSTATE
RADIOTHERAPY
Annette Haworth1,2, M Ebert3,4, H Reynolds1,2, Y Sun1, D Wrath5, M
DiFranco6, C Mitchell2, S Williams2,1
1Universtiy of Melbourne, Melbourne, VIC, Australia, 2Peter MacCallum
Cancer Centre, Melbourne, VIC, Australia, 3Sir Charles Gairdner Hospital,
Nedlands, WA, Australia, 4University of Western Australia, Nedlands, WA,
Australia, 5Queensland University of Technology, Brisbane, QLD, Australia,
6Medical University of Vienna, Vienna, Austria
Purpose: Traditionally, treatments for localized prostate cancer target the
entire gland. Several approaches have been proposed to target subvolumes
of the prostate for radical treatment. Proposed treatment options include
brachytherapy and/or external beam radiotherapy (using a stereotactic abla-
tive approach), either as a focal boost dose in combination with whole gland
treatment, or as a partial gland treatment. Currently there is a paucity of data
supportingmethods for defining target volumes, the prescribed dose (and dose
constraints to organs at risk) and methods for defining treatment efficacy. We
describe a quantitative biological model that incorporates multiparametric
MRI (mpMRI) to address these issues.
Materials and Methods: Traditional methods of radiation dose prescription
are based on empirical methods using data from large patient cohorts. The
biological model introduces a personalized approach to dose prescribing
that incorporates knowledge of tumour biology to predict tumour control
probability based on a non-uniform distribution of radiation. Using in vivo
mpMRI data from patients scheduled for radical prostatectomy, machine
learning techniques were developed to predict tumour location and tumour
cell density that subsequently function as input parameters for the biological
model.
Results: Sophisticated, mathematical algorithms that incorporate cell density
estimation demonstrated a highly sensitive method for automated tumor de-
lineation in mpMRI (AUC of ROC 0.81–0.94). Similar statistical methods
have demonstrated potential for mpMRI parameter/pharmacokinetic maps to
be correlated with tumor characteristics including tumor cell density, Gleason
Score and hypoxia. A retrospective 10-patient study demonstrated a biolog-
ical inverse optimization algorithm offers significant reductions in urethral
doses compared with conventional treatment approaches. Although post-
treatment mpMRI is challenging to interpret, there is evidence that local re-
currence can be identified.
Conclusion: Using mpMRI to define tumor location and tumor characteristics
provides an opportunity for developing a personalized approach to treating
localized prostate cancer.
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DIFFERENCES IN ACTIVATION OF THE URETHRAL MUSCLES
BETWEEN MEN WITH AND WITHOUT URINARY INCONTINENCE
AFTER RADICAL PROSTATECTOMY REVEALED BY TRANSPERINEAL
ULTRASOUND IMAGING
Paul W Hodges1, R Stafford1
1The University of Queensland, St Lucia, QLD, Australia
Up to 60% of men experience urinary incontinence after radical prostatec-
tomy (RP). Although continence improves, most continue to experience oc-
casional to severe urine loss with a major impact on quality of life. Mainte-
nance of continence requires coordinated function of multiple muscles that
pressurize the urethra. Surgical insult to urethral smooth and striated mus-
cle underpins incontinence after RP. Restoration and/or enhancement of this
function is the foundation for exercise to rehabilitate continence, but evidence
of efficacy has been questioned.1 Advances in rehabilitation are hampered
by lack of noninvasive methods to study function and recovery of urethral
muscles. This study aimed to use a new method (transperineal ultrasound
imaging)2 to study the urethral muscles in men with and without persistent
urinary incontinence after RP. Twenty-five men (48–75 years) participated in
the study 2–210 months after RP. Men who scored 5 on the ICS male short
form questionnaire were considered “incontinent.” In sitting, an ultrasound
transducer (8 MHz) was placed on the perineum in a sagittal alignment. Im-
ages were recorded during voluntary contraction and evoked cough (capsaicin
inhalation). Measures were compared between groups with t-tests, and re-
lationships assessed with Pearson’s correlation coefficient. During coughing
and voluntary contraction, continent men achieved greater dorsal displace-
ment of the mid-urethra (greater activation of the striated urethral sphincter3;
P = 0.01), and elevation or less depression of the urethrovesical junction
(greater activation of puborectalis to support the bladder against elevated
intra-abdominal pressure3; P = 0.01). Severity of incontinence was corre-
lated with mid-dorsal motion (cough: R = 0.52; voluntary: R = 0.42) and
urethrovesical junction displacement (R = 0.54; 0.56). These results show
that persistent incontinence after RP is related to poor control of urethral
muscles, but the pattern varied between individuals. This provides potential
targets for treatment, but interventions that target training of pelvic floormus-
cles to treat incontinence may need to be individualized to match the patient
presentation.
Asia-Pac J Clin Oncol 2016; 12(Suppl. 3): 34–43 C© 2016 The Authors. Asia-Pacific Journal of Clinical Oncology
C© 2016 Wiley Publishing Asia Pty Ltd
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PROSTATE CANCER XENOGRAFT IN VITRO CULTURE USING
ORGANOID TECHNOLOGY
Andre Joshi1,2, C. Nicholson1,2, A. Hutchinson1, G. Tevz1, B. Hollier1, S.
McPherson1, H. Rhee1,2, E. Williams1, I. Vela1,2
1Australian Prostate Cancer Research Centre - Queensland, Institute of
Health and Biomedical Innovation, Queensland University of Technology,
Princess Alexandra Hospital, Translational Research Institute, Brisbane,
QLD, Australia, 2Department of Urology, Princess Alexandra Hospital,
Brisbane, QLD, Australia
Introduction & Objectives: Prostate cancer is difficult to culture in vitro,
demonstrated by the limited number of cell lines. Alternative models such
as patient derived xenografts (PDXs) propagated in immunodeficient mice
have been a mainstay for the research community. These systems are limited
by their cost and inability to easily manipulate the cells genetically. Recent de-
velopment of organoid in vitro culture technology has led to the development
of multiple new in vitro prostate cancer cell line models.1 Using this technol-
ogy we have successfully grown in vitro PDXs for the first time, increasing
the utility of these models.
Methods: Three LuCaP PDX lines and a locally developed PDX line (BM18)2
were collected at time of passage. These tumors were digested in type II colla-
genase (Gibco) for 30 min and seeded in 150 μLMatrigelTM blobs or directly
onto collagen type I coated plates in prostate culture media (described in refer-
ence [1]). RT-qPCR comparison of various gene products of interest between
culture and PDX samples was performed. Transient and stable transfection of
in vitro cultured cells was performed using Lipofectamine 2000 (Lifesciences)
and pCMV6-AC-GFP empty vector (Origene) as per protocol. In vitro cul-
tures were injected subcutaneously at 1 × 105 cells in 200 μL MatrigelTM in
SCID mice.
Results: LuCaP and BM18 PDX lines were successfully cultured in vitro for
the first time. Transfection has produced for the first time GFP labeled LuCaP
and BM18 lines. In vitro cultures were successfully converted back to in vivo
tumors in immunocompromised mice.
Conclusion: Use of organoid in vitro culture technology has successfully
grown in vitro PDX models, some for the first time. This appears to not sig-
nificantly alter the phenotype of tumors and allows genetic manipulation of
these tumors for the first time in vitro, increasing the utility of these models
and potentially allowing novel findings and investigations.
References
1. Gao, D. et al. Organoid cultures derived from patients with advanced
prostate cancer. Cell 2014; 159 (1): 176–87.
2 McCulloch DR et al., BM18: a novel androgen-dependent human prostate
cancer xenograft model derived from a bone metastasis. Prostate 2005;
65 (1): 35–43.
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MULTIDISCIPLINARY TEAM APPROACH TO INTERPRETING PSMA
PET DATA IN MEN WITH PROSTATE CANCER
Arjna Kanagarajah1, H. Rhee1, I. Vela1, M. Lawson1, J. Munns1, E.
McCaffrey1, M. Lehman1, D. Pryor1, G. Malone1, J. Preston1, E. Chung1, P.
Heathcote1, S. Wood1
1Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia
Introduction: Detecting metastatic prostate cancer lesions with improved sen-
sitivity and specificity can help improve patient outcomes.
Aim: To determine the discrepancy between current standard imaging and
68 Gallium prostate-specific membrane antigen (PSMA) positron emission
tomography (PET) imaging with histopathological correlation.
Methods: Sixty-one patients were imaged to clarify in determinant lesions
on standard imaging. Histopathological specimens were available from 10
patients for correlation with 68 Ga PSMA PET.
Results: PET avid disease was observed in 53 patients. Eighty lesions were
identified and the distribution was 52.5% lymph node, 24% appendicular
skeleton, 16% Axial skeleton, and 7.5% visceral. Distribution of lymph node
positivity was 23% common iliac, 20% external iliac, 17% pelvic, 9% para-
aortic, 8% para-rectal, 8% internal iliac, 6% mediastinal lymph node in-
volvement, 3% retroperitoneal, 3% supraclavicular, and 3% presacral. PET
and computer tomography (CT) and bone scan were available for compar-
ison in 34 patients. Out of 34 patients, PET was able to identify previ-
ously unrecognized lesions in 24 patients. In these patients, treatment deci-
sions were changed. Ten patients had PET avid lesions sampled by surgery
(n = 5) or CT guided core biopsy (n = 5). Positive predictive value of PET
avid lesions was 100% in the 25 lesions analyzed. Loco-regional lymph node
dissection allowed for the calculation of sensitivity of 45% and specificity of
95%.
Conclusion: This study demonstrates alterations to the clinical management
of patients based on improved sensitivity and specificity of prostate cancer
molecular imaging.
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ALDO-KETO REDUCTASE 1C3(AKR1C3) RS12529 POLYMORPHISM A
CANDIDATE GENOTYPE TOWARDS SPECIFIC PSA TESTING
THRESHOLDS
Nishi Karunasinghe1, J. Masters2, M. Pokorny3, L. Ferguson1
1University of Auckland, Auckland, AUCKLAND, New Zealand, 2Urology
Department, Auckland District Health Board, Auckland, New Zealand,
3Urology, Wesley Medical Centre, Auchenflower, Brisbane, Australia
For over two decades, serum prostate-specific antigen (PSA) testing has been
the mainstay of prostate cancer diagnosis, but the test has been criticized for
its lack of specificity, resulting in both significant underdiagnoses and over-
diagnoses and overtreatment. PSA is produced subsequent to androgens bind-
ing to the androgen receptor (AR). Although the major source of androgen is
from the testes, the AKR1C3 enzyme, which is produced in many tissue types
including the adrenal gland, also converts androstenedione to testosterone
which is a likely source of other supplies of androgens.1
Our studies have shown that increasing frequency of recessive G allele of the
AKR1C3 rs12529 single nucleotide polymorphism (SNP) shows an associ-
ated lowering of the serum PSA level in men with prostate cancer (or vice
versa with those having the dominant allele C) compared to controls. The
effect appears to be compounded in men with this allele exposed to tobacco
smoke.2
Apart from the steroidal functions, the AKR1C3 enzyme is also involved in
metabolizing polycyclic aromatic hydrocarbons (PAHs) derived from envi-
ronmental and lifestyle exposures. The AKR1C3 rs12529 SNP is in linkage
disequilibrium with the promoter SNP rs19378453 and both are located close
to transcription factor binding sites. Therefore, these SNPs are likely to pro-
duce gene expression changes. The AKR1C3 rs12529 G allele is the minor
allele among Caucasian (46%) and major allele among East Asians.3
Our hypothesis is that the AKR1C3 rs12529 G allele predisposes men ex-
posed to tobacco or PAHs to lower serum PSA levels, while at the same time
harboring more aggressive and locally advanced prostate cancers, thereby
presenting a diagnostic challenge and clinical risk to these men. This hypoth-
esis needs testing with a substantial data set before bringing in to clinical
practice and ANZUP membership could be the best consortium to address
this.
References
1. Nakamura Y, Hornsby PJ, Casson P et al. Type 5 17beta-hydroxysteroid
dehydrogenase (AKR1C3) contributes to testosterone production in the
adrenal reticularis. J Clin Endocrinol Metab 2009; 94 (6): 2192-8.
2. Karunasinghe N, Lange K, Han D et al. Androgen pathway related gene
variants and prostate cancer association in Auckland men. Curr Pharma-
cogenomics Person Med 2013; 11 (1): 22-30.
3. Figueroa JD,Malats N,Garcia-Closas M et al.Bladder cancer risk and ge-
netic variation in AKR1C3 and other metabolizing genes. Carcinogenesis
2008; 29 (10): 1955–62.
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AN UNUSUAL CASE OF PERITONEAL METASTASIS FROM PROSTATE
CANCER
Rahul Ladwa2,1, E. McCaffrey2,1, K. Miles2,1, K. O’Byrne3,1
1Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia,
2School of medicine, University of Queensland, Brisbane, QLD, Australia,
3Queensland University of Technology, Brisbane, QLD, Australia
Introduction: Prostate cancer is the second cause of cancer-related death in
men, and accounts for 13% of all cancer deaths in Australian men. The most
frequent sites of metastasis include bone (90%), lung (46%), liver (25%),
pleura (21%), and adrenals (13%).1 The omentum is an extremely rare
metastatic site for prostatic adenocarcinoma.
Methods: We present a rare case report of a patient who presented to our de-
partment with omental disease and malignant ascites secondary to advanced
prostate cancer and review the literature.
Results: A 74-year-old male with metastatic castrate-resistant prostate cancer,
treated with Docetaxel chemotherapy and abiraterone acetate, developed dis-
ease progression with serial rising prostate-specific antigen (PSA) levels over
6 months with a PSA doubling time of 2 months. A computerized tomogra-
phy (CT) demonstrated omental infiltration with tumor. Given the unusual
pattern of disease, a prostate-specific membrane antigen (PSMA) positron
emission tomography (PET)-CT scan was performed revealing uptake in the
tumor within the prostate bed and with extensive avid omental disease. A CT-
guided omental biopsy revealed tumor cells positive for prostate-specific acid
phosphatase and PSA consistent with metastatic prostate adenocarcinoma.
Cabazitaxel chemotherapy was instituted with a PSA biochemical response
from 200 to 99 after two cycles of therapy. Repeat staging with PSMA PET-
CT imaging revealed stable disease.
Discussion: The omentum is an extremely rare metastatic site for spread of
prostatic adenocarcinoma, with only a few cases published in the literature.
Transcoelomic cancer spread may occur differing from traditional known
mechanisms of lympho-vascular spread and the “seed and soil” hypothe-
sis. This is the first case of imaging omental prostate cancer with a PSMA
PET-CT scan and of treatment of omental spread of disease with Cabazitaxel
chemotherapy.
Reference
1. Saiton H et al. Metastatic patterns of prostatic cancer. Correlation be-
tween sites and number of organs involved. Cancer 1984; 54 (12): 3078–
84.
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PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF
DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT
PROSTATE CANCER (mCRPC)
Kate Mahon1,2, H-M Lin2, C Spielman2, M Lee-Ng3, H Gurney4, G
Mallesara5, M Stockler6, K Briscoe7, G Marx8, SN Breit3, D Brown3, L
Horvath2,1
1The Chris O’Brien Lifehouse, Camperdown, Australia, 2Garvan Institute
of Medical Research, Darlinghurst, Australia, 3St Vincent’s Centre for
Applied Medical Research, Darlinghurst, Australia, 4Westmead Hospital,
Westmead, Australia, 5Calvary Mater Newcastle Hospital, Waratah,
Australia, 6NHMRC Clinical Trials Centre, Camperdown, Australia, 7Coffs
Harbour Base Hospital, Coffs Harbour, Australia, 8Northern Haematology
and Oncology Group, Sydney Adventist Hospital, Wahroonga, Australia
Background: Docetaxel (DTX) improves symptoms and survival in metastatic
castrate-resistant prostate cancer (mCRPC); however, approximately 50% of
patients have chemoresistant disease. Early biomarkers of chemoresistance
allow rapid cessation of ineffective therapy and progression to other avail-
able treatments. Increased levels of circulating macrophage inhibitory cy-
tokine 1 (MIC1), IL4 and IL6 after cycle 1 of DTX predicted chemoresis-
tance in a phase I exploratory cohort of men with mCRPC. This phase II
biomarker study aims to validate these findings in an independent patient
cohort.
Methods: Plasma samples pre-cycle 1 and pre-cycle 2 DTX were collected
from 121 men with mCRPC. MIC1, IL4, and IL6 levels were measured by
ELISA. Patients were grouped as partial responders (PR) and nonresponders
(progressive or stable disease) based on prostate-specific antigen (PSA) re-
sponse criteria. Associations between cytokine levels, response, and overall
survival (OS) were assessed.
Results: After one cycle of DTX, non-responders had significantly greater in-
creases inMIC1 (P< 0.001) and IL6 (P= 0.048).OnROC analysis, chemore-
sistance was predicted by early changes in MIC1 (AUC 0.7; P < 0.001). In
contrast to our phase I analysis, IL4 was not associated with response. Fur-
thermore, combinations of cytokine changes did not improve on MIC1 alone
as an early biomarker of response. Higher levels of MIC1 at baseline and af-
ter cycle 1 DTX predicted shorter OS (HR 1.2; 95% confidence interval [CI],
1.0–1.4; P = 0.03; and HR 1.3; 95% CI, 1.1–1.5; P = 0.004, respectively).
In a multivariable model, baseline Hb (P = 0.01), baseline MIC1 (P = 0.08),
and post DTXMIC1 (HR 1.9; 95% CI, 1.1–3.4; P = 0.02) were independent
predictors of OS.
Conclusions: This phase II biomarker study has validated the utility of MIC1
as an early predictor of chemoresistance and OS in mCRPC. Conversely, IL4
and IL6 have not demonstrated additional value, emphasizing that adherence
to a standardized biomarker development pathway is essential to efficiently
move biomarkers into clinical practice. Independent phase III validation of
MIC1 is now underway.
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“HOW DID I GET HERE, WHERE DID I COME FROM?” AN AUDIT OF
PATIENT REFERRAL AND RECRUITMENT INTO GENITOURINARY
CANCER CLINICAL TRIALS
Lauren E Mitchell1, P Parente2, ID Davis2, CJ Pezaro2
1Eastern Health Clinical School, Monash University, Melbourne, VIC,
Australia, 2Cancer Services, Eastern Health, Box Hill, VIC, Australia
Background: Many standard treatment options exist for patients with geni-
tourinary (GU) cancer. Depending on the cancer type and clinical stage, pa-
tients may be offered surgery, radiation, hormone therapy, and anticancer
or chemotherapy treatments. Clinical trials are readily offered as an alterna-
tive to standard treatment. However, ensuring that patients are appropriately
counseled regarding treatment options and referred in a timely manner, can
present a challenge for trial recruitment. We examined the referral process
for patients recruited to GU oncology clinical trials, to determine where pa-
tients were referred from, and how these patients were identified as potential
clinical trial patients.
Method: Medical records of patients recruited to GU oncology clinical tri-
als in a major tertiary hospital in Melbourne were examined for the period
January 2014 to April 2016. Time from referral to consent was
recorded, along with the professional group of the referring clinician.
Time to trial randomization was also recorded. Descriptive statistics were
performed.
Results: A total of 61 patients signed consent for 10 clinical trials (90%
prostate, 9% renal, 1% testicular) during the 27 months examined. The ma-
jority of patient referrals (30, 49%) originated within the multidisciplinary
team (MDT), which included Urology and Radiation Oncology referrals. A
further 13 (21%) of referrals were from private oncologists. The median time
from referral to clinical review was 18 days (range 0–524). Of consented pa-
tients, 47 were randomized, a median of 15 days after consent.
Conclusion: This audit highlights the importance of the MDT and referring
clinicians in successful recruitment to GU oncology clinical trials. Regular up-
dates on the trials being conducted can facilitate referral from both internal
and external clinicians. Monitoring time from referral to consent and ran-
domization can assist research teams in streamlining processes, and increasing
satisfaction with trial participation.
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ACUTE AND LATE URINARY TOXICITY PROFILES FOLLOWING
PERMANENT SEED BRACHYTHERAPY FOR LOCALIZED PROSTATE
CANCER
Wee Loon Ong1,2, JL Millar1,2
1Alfred Health Radiation Oncology Service, Prahran, VIC, Australia,
2Alfred Health Radiation Oncology Service, Prahran, VIC, Australia
Aim: To evaluate acute (AUT) and late urinary toxicities (LUT) following
permanent seed brachytherapy (BT).
Methods: The is a prospective study of 733 consecutive patients treated
with BT at a single institution (1999–2012), who completed the Interna-
tional prostate symptom score (IPSS) questionnaire pre-BT, with minimum
12-month follow-up. Logistic regression was used to assess the patient, tu-
mor, treatment factors, and risk of AUT (acute urinary retention 60 days
post-BT). The probability of LUT (restricted flow requiring interventions, i.e.
at least a dilatation) and IPSS resolution (IPSS return to2-points of baseline
IPSS) were estimated using the Kaplan–Meier methods. Multivariate Cox-
regressions were used to estimate the effect of each factors on LUT and IPSS
resolution.
Results: Seventy-four (10%) patients had cytoreductive ADT pre-BT; 180
(24%) had TURP at a median of 3 months pre-BT (range: 2–13 months).
The median pre-BT maximum urinary flow rate (maxflow) was 20 mL/s. The
median baseline IPSS was 4 (range: 0–22). The patients were followed for a
median of 60 months (range: 12–134 months).Ninety percent (12%) patients
developed AUT at a median of 1-day post-BT (range: 0–52). In multivariate
logistic regressions, patients with NCCN intermediate risk PCa (odds ratio
[OR] = 1.93; 95% confidence interval [CI] = 1.10–3.40) and larger prostate
(OR 1.05; 95% CI = 1.01–1.10) had higher risk of AUT, whereas those with
higher pre-BT maxflow (OR 0.95; 95% CI, 0.92–0.98) and pre-BT TURP
(OR 0.31; 95% CI, 0.14–0.70) had lower risk of AUT. A total of 129 (18%)
patients developed LUT at a median of 27 months post-BT. In multivariate
Cox-regressions, older patients (OR 1.03, 95%CI, 1.01–1.06) and those with
pre-BT TURP (OR 1.8; 95% CI, 1.2-2.6) are more likely to have LUT. A total
of 626 (85%) patients achieved IPSS resolution at median of 9 months post-
BT (range: 1–112months). In multivariate Cox regression, older patients (OR
1.02; 95% CI, 1.01–1.03), those who had pre-BT ADT (OR 1.65; 95% CI,
1.27–2.15), and pre-BT TURP (OR 2.15; 95% CI, 1.76–2.63) are more likely
to achieve IPSS resolution.
Conclusion: We reported comparable rate of AUT and LUT with literature.
The large majority of patients achieved IPSS resolution after BT.
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CASE SERIES: SILENT MALIGNANT SPINAL CORD COMPRESSION
(MSCC) SECONDARY TO SPINAL EPIDURAL METASTASES (SEM) IN
CASTRATE-RESISTANT PROSTATE CANCER (CRPC)
John J Park1, D Sabanathan1,2, A Lau1, H Gurney1,2
1Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead,
NSW, Australia, 2Medical Oncology Department, Macquarie University
Hospital, Macquarie, NSW, Australia
Background: Spinal epidural metastasis (SEM) secondary to castrate-resistant
prostate cancer (CRPC) is an uncommon phenomenon – usually presenting in
heavily pretreated patients, often as a preterminal event. The recent introduc-
tion of newer anti-androgen therapies, enzalutamde and abiraterone acetate
as second-line therapy for CRPC has greatly impacted on the overall survival
of patients with CRPC but may be changing the pattern of disease. Here we
report four cases of “silent”malignant spinal cord compression (MSCC) sec-
ondary to SEM in patients receiving enzalutamide before chemotherapy.
Method: Four patients diagnosed with metastatic CRPC were commenced
on enzalutamide on clinical trials. None had received chemotherapy. Baseline
scans in all patients demonstrated extensive bony disease and lymph node
involvement. All patients experienced initial response to treatment with fall
in prostate-specific antigen (PSA; median fall of 54%). In all four cases, clin-
ical presentation of MSCC was sudden and unexpected with no prodromal
neurological symptoms, with PSA levels either stable or slowly rising, and CT
scans and whole body bone scans showed stable disease in known metastatic
sites.Whole spineMRI on presentation of neurological deficits showed epidu-
ral and dural metastases. MSCC occurred at median of 11.4 months after
starting enzalutamide. Three patients did not respond to radiotherapy after
MSCC; however, one patient continued to chemotherapy with good recovery
of neurological function.
Conclusion: Clinicians should be aware of this change in the pattern of CRPC,
with the onset of MSCC secondary to SME with minimal warning and de-
spite otherwise stable disease, in patients treated with newer anti-androgen
therapies. Further research into the escape mechanisms and development of
SEM in patients treated with enzalutamide and abiraterone is required.
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OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR
OLIGMETASTATIC RECURRENT PROSTATE CANCER AFTER RADICAL
PROSTATECTOMY: RESULTS OF A SINGLE-INSTITUTION
MULTIDISCIPLINARY TEAM SERIES
Amit Patel1, H. Rhee2,3, P. Heathcote2, M. Lawson2, J. Preston2, I. Vela2,3, D.
Pryor4,3, M. Lehman4,3, S. Wood2,3
1Queensland Health, Woolloongabba, QLD, Australia, 2Urology, Princess
Alexandra Hospital, Brisbane, QLD, Australia, 3The Australian Prostate
Cancer Research Centre, Brisbane, QLD, Australia, 4Radiation Oncology,
Princess Alexandra Hospital, Brisbane, QLD, Australia
Background: Despite primary treatment of localized prostate cancer with
surgery or radiotherapy, a significant number of patients will eventually de-
velop biochemical recurrence. To date, small metastatic foci have been diffi-
cult to characterize using standard imaging modalities. prostate-specific mem-
brane antigen (PSMA) positron emission tomography (PET) has recently
been introduced to allow for early detection. Prostate cancer lymph node
metastatic recurrence is commonly managed with either radiation therapy
or androgen-deprivation therapy. Surgical lymph node dissection has been
recently trialed as an alternative option in select patients.
Objective: To assess the outcomes of salvage lymph node dissection in pa-
tients who had detectable lesions on PSMA PET and relapse oligometastatic
prostate cancer (CaP) post radical retropubic prostatectomy treated with sal-
vage lymph node dissection.
Design, setting, participants: We retrospectively reviewed records of patients
treated with salvage lymph node dissection for oligometastatic CaP from the
Princess Alexandra Hospital Prostate Cancer Multidisciplinary Team meet-
ing. Biochemical response is defined as a biochemical reduction in prostate-
specific antigen after surgery.
Intervention: Pelvic LND
Outcome measurements and statistical analysis: Over 12 months, 96 patients
had PSMA imaging, 42 had PET MRI, 60 had PET CT), 66 were for bio-
chemical recurrence, and 48 patients had oligometastatic disease.
Conclusions: Patient selective salvage LND may be a useful alternative ther-
apeutic option for patients with oligometastatic recurrence. Roughly 60% of
patients achieved biochemical response.
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ZERO HOSPITAL ADMISSIONS FOR INFECTION AFTER 1024
TRANSPERINEAL PROSTATE BIOPSIES
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Introduction and Purpose: Transperineal biopsy (TPB) has been associated
with an exceedingly low rate of serious infection. The aim of this study was
to determine the rate of hospital admissions for infection after transperineal
biopsy of prostate.
Materials and Method: A total of 1061 consecutive patients underwent
transperineal biopsy of the prostate (TPB) betweenMay 2012 and April 2016
by a private group urology practice, performing TPB at multiple hospitals
acrossMelbourne. They had various antibiotic prophylaxis regimes.Data col-
lected from these patients were entered into an ethics approved prospective
database including prophylactic antibiotics used and post-operative compli-
cations.
Results: A total of 1061 consecutive patients underwent TPB. Initially pa-
tients were treated with quinolone prophylaxis and then later 594 consecu-
tive patients received cephazolin only. None were readmitted to hospital with
infection. Seven patients developed acute urinary retention and one patient
was treated in the community with oral antibiotics for prostatitis.
Conclusion: Sepsis post-TPB is an exceedingly rare complication, with a 0%
rate in this study. It is safe to use single-dose cephazolin only as antibiotic
prophylaxis prior to TPB, negating the need for quinolones. This study sup-
ports the current Therapeutic Guidelines recommendation for TPB prophy-
laxis.Whether any antibiotic prophylaxis is needed at all for TPB is the subject
of a future study.
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A NEW REGISTRY OF MRI IN PROSTATE CANCER DIAGNOSIS USING
THE REDCAP ELECTRONIC DATA CAPTURE PROGRAM
Lana Pepdjonovic1, S Huang1, A Dat1, S Mann1, M Frydenberg1,2, D
Moon1,3,4, U Hanegbi1, A Landau1, R Snow1, R O’Sullivan5, A Ryan6, J
Grummet1,2,7
1Australian Urology Associates, Melbourne, Victoria, Australia,
2Department of Surgery, Monash University, Melbourne, Victoria, Australia,
3Department of Surgery, Epworth Healthcare, Melbourne, Victoria,
Australia, 4Department of Surgery, University of Melbourne, Melbourne,
Victoria, Australia, 5Department of Radiology, Epworth Healthcare,
Melbourne, Victoria, Australia, 6TissuPath Pathology, Melbourne, Victoria,
Australia, 7Department of Urology, Alfred Health, Melbourne, Victoria,
Australia
Introduction: There is a burgeoning literature on the utility ofMRI in prostate
cancer diagnosis. The rapid uptake of this diagnostic modality requires gran-
ular data capture for quality assurance of its purported diagnostic accuracy.
We aimed to create a web-based registry enabling multicenter user-friendly
real-time data entry for this purpose.
Materials and Methods: The REDCap application was accessed through
Monash University as a partner in the worldwide REDCap consortium.A reg-
istry was built for men undergoing MRI for suspicion of significant prostate
cancer (either as a new diagnosis or on active surveillance for previously di-
agnosed low-risk disease). The registry was created using REDCap’s Online
Designer.
Results: Eighteen granular data collection instruments were created, includ-
ing instruments for patient demographics,MRI findings, transperineal biopsy
results, prostatectomy specimen pathology, and repeated MRI and biopsy
findings for active surveillance. Instruments included dropdown boxes and
branching logic for ease of data entry. To date, the registry has been popu-
lated on 995 consecutive patients.
Conclusion: The rapid uptake of MRI in prostate cancer diagnosis requires
large volume multicenter data capture for quality assurance. REDCap ap-
pears to be a suitable application for this purpose. To our knowledge this is
the first registry of prostate MRI using REDCap. This web-based program fa-
cilitates multicenter collaboration, real-time data entry, and automatic export
into common statistical packages.
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MPMRI IS HELPING TO AVOID UNNECESSARY PROSTATE BIOPSIES
IN THE DIAGNOSTIC WORK-UP OF PROSTATE CANCER
Lana Pepdjonovic1, S Huang1, A Dat1, S Mann1, M Frydenberg1,2, D
Moon1,3,4, U Hanegbi1, A Landau1, R Snow1, R O’Sullivan5, A Ryan6, J
Grummet1,2,7
1Australian Urology Associates, Melbourne, Victoria, Australia,
2Department of Surgery, Monash University, Melbourne, Victoria, Australia,
3Department of Surgery, Epworth Healthcare, Melbourne, Victoria,
Australia, 4Department of Surgery, University of Melbourne, Melbourne,
Victoria, Australia, 5Department of Radiology, Epworth Healthcare,
Melbourne, Victoria, Australia, 6TissuPath Pathology, Melbourne, Victoria,
Australia, 7Department of Urology, Alfred Health, Melbourne, Victoria,
Australia
Introduction: Multiparametric magnetic resonance imaging (mpMRI) of the
prostate may have a role in prostate cancer diagnosis in reducing the need
for prostate biopsies in selected patients. This change in practice has been
occurring in the management of patients in a private group urology practice.
Materials and Method: A custom made REDCap electronic database was
used to capture the results of patients who had a mpMRI between June
2013 and January 2016. Information collected included patient age, prostate-
specific antigen, Prostate Imaging Reporting and Data System (PI-RADS)
score, transperineal biopsy of the prostate (TPB) results and initial manage-
ment.
Results: Of 473 patients undergoing mpMRI, 35 patients had PIRADS 1 and
224 patients PI-RADS 2. Only 37.1% and 33.9% of patients with PIRADS
1 and 2 had a subsequent biopsy, respectively. This is in contrast with 62.5%
of PI-RADS 3, 95.8% of PI-RADS 4, and 87.2% of PIRADS 5 patients who
went on to have a TPB. The 16 patients who had PIRADS 4 or 5 disease on
mpMRI who did not have a TPB had multiple medical comorbidities.
Conclusion: mpMRI is being used in current clinical practice to avoid biopsy
in the diagnostic work-up of prostate cancer in selected patients. However,
some patients with negative MRI will have significant disease and therefore
those not undergoing a biopsy will need to be followed up closely.
abs#118
THE DIAGNOSTIC ACCURACY OF MULTIPARAMETRIC MRI FOR
SIGNIFICANT PROSTATE CANCER WHEN COMPARED TO
TRANSPERINEAL BIOPSY
Lana Pepdjonovic1, S Huang1, A Dat1, S Mann1, M Frydenberg1,2, D
Moon1,3,4, U Hanegbi1, A Landau1, R Snow1, R O’Sullivan5, A Ryan6, J
Grummet1,2,7
1Australian Urology Associates, Melbourne, Victoria, Australia,
2Department of Surgery, Monash University, Melbourne, Victoria, Australia,
3Department of Surgery, Epworth Healthcare, Melbourne, Victoria,
Australia, 4Department of Surgery, University of Melbourne, Melbourne,
Victoria, Australia, 5Department of Radiology, Epworth Healthcare,
Melbourne, Victoria, Australia, 6TissuPath Pathology, Melbourne, Victoria,
Australia, 7Department of Urology, Alfred Health, Melbourne, Victoria,
Australia
Introduction: The aim of this study was to determine the accuracy of mul-
tiparametric magnetic resonance imaging (mpMRI) of the prostate in diag-
nosis of significant prostate cancer (Grade group 2 and above) in patients
with no history of prostate cancer, by directly comparing it to the results of
transperineal biopsy of the prostate (TPB) when taking template cores as well
as targeted cores where mpMRI is positive.
Materials and Method: A total of 437 patients who had no previous history
of prostate cancer had a mpMRI between the study period of June 2013 and
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January 2016, of these 243 patients had a subsequent TPB. These results were
analyzed from a custommade REDCap electronic data capture program. The
correlation between Prostate Imaging Reporting and Data System (PIRADS)
score and TPB histology was calculated.
Results: mpMRI reported that 160 patients as possibly, likely or highly likely
as having clinically significant prostate cancer (PIRADS 3,4,5) and 83 patients
as not having suspicious features on their imaging (PIRADS 1,2). TPB diag-
nosed 132 patients with clinically significant cancer and 111 patients showed
no evidence of significant prostate cancer. mpMRI has a sensitivity of 83.3%
for significant prostate cancer; however, its specificity is lower at 55%.
Conclusions: mpMRI is a valuable diagnostic tool for prostate cancer in
conjunction with prostate-specific antigen density, digital rectal exam, and
TPB. Its high sensitivity allows judicious use of TPB among patients. mpMRI
should be used prior to TPB in prostate cancer diagnosis as suspicious lesions
can be targeted.
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RELATIONSHIPS BETWEEN URINARY FUNCTION, SEXUAL
FUNCTION, AND MASCULINE SELF-ESTEEM IN MEN FOLLOWING
RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER
Brindha Pillay1, B Wright2, AC Wootten1, M Botti2
1Epworth HealthCare, Richmond, Victoria, Australia, 2Deakin Centre of
Clinical Nursing Research, Richmond, Victoria, Australia
Objective: Radical prostatectomy (RP) has routinely been used to treat lo-
calized prostate cancer. Despite surgical advancements, postoperative urinary
incontinence and sexual dysfunction continue to affect patients. Preliminary
evidence suggests that sexual and urinary outcomes of patients post-RP may
be related and potentially mediated by changes in masculine self-esteem. This
study assessed how changes in urinary function and masculine self-esteem are
related to sexual outcomes postsurgery.
Methods: Between April 2009 and February 2013, consecutive patients un-
dergoing RP were recruited from urology practices as part of a larger study.
In this study, urinary and sexual function, and masculine self-esteem data
were obtained using the Expanded Prostate Cancer Index Composite and
Prostate Cancer Related Quality of Life Scale. Changes in patient outcomes
were assessed longitudinally over two time periods: 4 weeks to 6 months and
6 months to 24 months postsurgery.
Results: The survey was completed by 942 patients at 4 weeks postsurgery,
and they were followed longitudinally over 24 months. Over the course of
the study, 927 participants were retained. Results indicated a weak relation-
ship between change in urinary outcomes and sexual outcomes. Change in
urinary outcomes positively predicted change in masculine self-esteem for
both time periods assessed. A change in masculine self-esteem positively pre-
dicted sexual outcomes at 6 and 24 months postsurgery. Masculine self-
esteem change did not mediate the relationships between urinary and sexual
outcomes.
Conclusions: Men who reported a decrease in masculine self-esteem, partic-
ularly in the latter period of recovery, were more likely to experience poorer
sexual outcomes. It may be important to assess men for changes in masculine
self-esteem post-RP. This may allow the early identification of patients who
require psychosocial support to develop more flexible ways of constructing
their masculinities and adjusting to altered sexual functioning.
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RADICAL PROSTATECTOMY OUTCOMES IN MEN AGED >75 IN
VICTORIA
W Ranasinghe1, L Wang1, D Bolton1, Shomik Sengupta2
1Monash Health, Hawthorn East, VIC, Australia, 2Department of Urology,
Austin Health/ University of Melbourne, Melbourne, Australia
Aims: We aimed to investigate the outcomes of patients older than 75 years
in Victoria undergoing radical prostatectomy (RRP) for prostate cancer (PC).
Methods: All men undergoing RRP in Victoria between January 1, 2004 and
December 31, 2014 were obtained from the Victorian Cancer registry. Tumor
characteristics of Gleason grade and stage of disease as well as cause of death
were also obtained. Statistical analysis were performed using Chi squared,
cox proportional hazard method, and Kaplan–Maier curves.
Results: A total of 14686 men underwent RRP during the defined period with
a median follow up of 58months. Three hundred and thirty-two of these were
men over the age of 75. Men >75 years had a higher proportion of Gleason
8 disease (16.6% vs 11.4%, P < 0.001) but had similar stage of disease.
Men >75 had higher rates of 5- and 10-year overall mortality (67.3% vs
96.3% and 27.7% vs 89.1%), PC-specific mortality (96.2 vs 99.3 and 94.3
vs 97.4), respectively. Men >75 had higher rates of deaths from other causes.
Age was an independent risk factor for PC specific and overall mortality on
multivariate analysis (hazard ratio [HR] 1.49; 95% CI, 1.32–1.68; P< 0.001
and HR 4.26; 95% CI, 2.15–8.42; P < 0.001), when adjusted for stage and
grade.
Conclusion: Older men (>75 years) undergoing RRP in Victoria had higher
grade disease but similar stage. Age was an independent risk factor for worse
prostate cancer specific and overall survival.
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PSMA PET IMPROVES DIAGNOSTIC ACCURACY OF MPMRI IN
LOCALIZED PROSTATE CANCER AS CONFIRMED BY WHOLE MOUNT
HISTOPATHOLOGY: IMPLICATIONS FOR SELECTION AND
ASSESSMENT FOR ACTIVE SURVEILLANCE AND FOCAL THERAPY
Handoo Rhee1, P Thomas, B Shepherd, S Greenslade, I Vela, Pamela J Russell,
C Nelson, S Wood, P Heathcote
1Australian Prostate Cancer Research Centre - Queensland, Princess
Alexandra Hospital, Woolloongabba, QLD, Australia
Introduction: In this study, we compare mpMRI prostate and PSMA PET
with whole-mount ex vivo prostate histopathological evaluation to determine
the sensitivity and specificity of PSMA PET and mpMRI for detecting and
locating tumour foci within the prostate.
Methods: Twenty-two patients with a diagnosis of localized prostate cancer
based on standard transrectal ultrasound guided biopsy of prostate and a
planned retropubic radical prostatectomy were recruited from the Princess
Alexandra Hospital (PAH) and Greenslopes Private Hospital. Patients under-
went mpMRI and PSMA PET a minimum of 4 weeks post prostate biopsy,
with surgery being performed within 6 weeks of the imaging studies (either
mpMRI or PSMA PET). Twenty patients were eligible for evaluation.
Results: There were 71 lesions or regions of interest (ROIs) identified from the
whole-mount histopathological analysis. According to the UCL definition 1,
50 lesions were identified as being clinically significant (Table 1). 13 patients
(65%) had T2 disease, whilst 7 patients had T3 disease. Total Gleason score
of 7 (3 + 4 or 4 + 3 with/without tertiary 5) was the most common final
histopathology result (80%, n = 16/20). Multifocal disease was observed in
80% (n = 16) of patients. Sensitivity and PPV of mpMRI were 42% and
81%, respectively. For PSMA PET, sensitivity and PPV was 40% and 91%
(Table 2). In a patient, a tumor was more likely to be identified by mpMRI,
whereas it was more likely to be truly positive on PSMA PET.
Conclusion: This study to our knowledge is the first comparison of mpMRI,
PET using 68Ga-PSMA-HBED-CC, and whole mount histopathological anal-
ysis of the prostate in a localized disease setting. The sensitivity, specificity,
PPV and NPV of mpMRI, and PSMA PET are shown to be comparable in
the patient population of this study.
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Objective: To determine the prognostic and metabolic benefits of metformin
in those starting androgen deprivation therapy (ADT) for newly diagnosed
metastatic prostate cancer.
Methods: Androgen deprivation therapy and adjuvant metformin (ADMET)
trial is a single blinded, multi-site (Princess Alexandra Hospital, Gold Coast
Hospital, Epworth Healthcare Centre), randomized, placebo controlled,
2-year, prospective clinical trial. The study has been open for recruitment
since September 2014. In total, 80 patients with metastatic prostate cancer
who are commenced on ADT are expected to be recruited. Patients are re-
viewed every 6–12 weeks (site specific) for the assessment of physical and
serum measurements, and circulating tumor cells (CTCs).
Results: In the last 14 months, sixty patients have been screened and 25 pa-
tients recruited into the clinical trial. Thirteen patients were diagnosed with
metabolic syndrome and five with diabetes at the time of starting ADT. At
screening, 21 of 25 patients demonstrated circulating tumour cells with the
mean number of 780 (range 1–4750, ±1140). At 3 months, 20 patients were
available for comparative analysis. Patients demonstrated significant changes
(%) in weight (0.45 ± 2.21), prostate-specific antigen (−92.33 ± 5.25), total
cholesterol (8.54± 18.24), triglyceride (11.01± 34.23), high density lipopro-
tein (15.32 ± 28.31), low-density lipoprotein (12.58 ± 20.86), fasting glu-
cose 0.84 ± 20.12), fasting insulin (12.23 ± 99.21) and homeostatic model
assessment-insulin resistance score (19.12 ± 85.82). Unexpectedly, the num-
ber of CTCs increased at 12–24 weeks in most patients after uniform decline
in number at 6 weeks.
Conclusions: Although ADT remains a core component of treating men with
metastatic prostate cancer, it is associated with metabolic syndrome and asso-
ciated morbidities such as cardiovascular disease and diabetes. At the conclu-
sion of this clinical trial, we aim to determine whether metformin has a role in
minimizing the risk of metabolic aberration caused by ADT and if prognostic
benefit could result from the therapy.
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PROSTATIC FLUID MRNA AND MICRORNA BIOMARKERS: AN
EMERGING PARADIGM FOR NONINVASIVE DIAGNOSIS OF
PROSTATE CANCER
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Brisbane, QLD, Australia, 12Aquesta Pathology, Brisbane, QLD, Australia,
13Anatomical Pathology, Pathology Queensland, Brisbane, QLD, Australia,
14Edith Cowan University, Joondalup, WA, Australia
Background: Biomarkers that accurately detect clinically significant prostate
cancer are urgently required. Natural prostate-specific biofluids, such as ejac-
ulate and post-ejaculate urethral washings (PEUW), contain prostate-specific
molecules warranting interrogation.We sought to evaluate the diagnostic per-
formance of mRNA and microRNAmarkers in ejaculate and PEU to comple-
ment serum prostate-specific antigen (PSA) in detecting clinically significant
prostate cancer.
Methods: From a prospectively collected biobank, ejaculate (n = 152) and
PEUW (n = 95) samples underwent prostatic cell RNA isolation, amplifica-
tion and qPCR for β2-microglobulin (β2M), PSA, PCA3, and Hepsin. Ade-
quate RNA for all assays was obtained for 66 ejaculate and 38 PEU samples.
Deep small RNA sequencing was performed for 49 ejaculate samples, with
candidate microRNAs undergoing qPCR. Findings were compared with de-
pendent clinical variables, including absolute (positive/negative) and clinically
significant (present/absent) cancer. Diagnostic performance was determined
using multivariate logistic regression modelling and receiver operating char-
acteristic analysis.
Results: Hepsin: PCA3 in ejaculate together with serum PSA was shown best
predict absolute (AUC = 0.724 vs 0.676) and clinically significant (AUC =
0.701 vs 0.680) prostate cancer. For 38 patients with adequate mRNA iso-
lated in ejaculate and PEU, PCA3:PSA in ejaculate (AUC 0.668) and PEU
(AUC 0.569) were comparable to serum PSA (AUC 0.617) in predicting ab-
solute prostate cancer status. Matched mRNA and microRNA expression
was possible for a subgroup of patients, with miR-200c (AUC = 0.788) and
miR-375 (AUC = 0.758) performing best. Serum PSA combined with miR-
200c and miR-125b improved prediction of absolute prostate cancer (AUC
= 0.869 vs 0.672; P < 0.05), improving specificity (67%) at 90% sensitiv-
ity compared with PSA alone (11%). All microRNAs were significantly (P <
0.005) elevated in primary tumors compared with patient-matched normal
tissues in an independent tissue cohort.
Conclusion: Prostatic fluid biomarkers together with serum PSA are predic-
tive of clinically significant prostate cancer. Further investigation with sen-
sitive detection methods may further improve diagnostic performance to be
helpful in triaging patients for MRI and biopsy, when confirmed by larger
studies.
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ERECTILE FUNCTION FOLLOWING TRANSPERINEAL PROSTATE
BIOPSY: A PROSPECTIVE LONGITUDINAL STUDY OF 170 PATIENTS
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Associates, Melbourne, Victoria, Australia, 3Epworth Healthcare,
Melbourne, Victoria, Australia
Introduction &Objectives: Data on erectile dysfunction (ED) associated with
prostate biopsy is limited and heterogeneous.1 Transperineal prostate biopsy
(TPB) has increasingly been utilized by Urologists due to negligible rates of
sepsis combined with better sampling of the prostate.2 This study aims to
evaluate the impact of TPB on erectile function.
Method: All patients undergoing TPB at a private group practice of seven
Urologists were enrolled in this ethics approved study. Patients were provided
the validated Sexual Health Inventory for Men (SHIM) questionnaire3 (aka
IIEF-5) at pre-biopsy and at 1, 3, and 12 months follow-up. Patients who
had undergone subsequent treatment including prostatectomy, radiation, or
androgen deprivation therapy, were excluded from analysis.
Results: Between October 2013 and May 2015, 170 patients had completed
a baseline SHIM questionnaire and at least one other follow-up SHIM ques-
tionnaire. The mean age was 63.3 years (SD 7.2), mean pre-biopsy PSA
was 7.8 ng/mL (SD 0.8) and median number of biopsy cores taken was 24
(IQR 22–24). Within this cohort, 60% (102/170) had initial biopsies, 11.1%
(19/170) had previous negative TRUS biopsies and 28.9% (49/1770) had
their biopsy as part of active surveillance.
A total of 156 (91.8%), 30 (17.6%), and 38 (22.4%) patients had recorded
baseline and follow-up SHIM questionnaires at 1, 3 and 12 months, respec-
tively. The mean change in SHIM scores between baseline and follow-up was
−2.18 (P < 0.001), −2.77 (P = 0.0154), and −1.29 (P = 0.0061) after 1, 3,
and 12 months, respectively. There was no statistically significant difference
between patients diagnosed with cancer and those without cancer diagnosis
at any stage of follow-up.
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Conclusions: There appears to be a mild reduction in erectile function after
TPB. Although this effect is mild and improves over time, patients should be
counselled regarding this possible outcome prior to biopsy.
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PROSTATECTOMY – A SINGLE SURGEON SERIES
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Introduction & Objectives: The increasing incidence of prostate cancer (PC)
with advancing age coupled with longer life expectancy is resulting in a grow-
ing number of older men being newly diagnosed disease. Many of these men
may be fit enough and wish to consider surgical treatment for PC, but con-
cerns persist over functional outcomes. The aim of this study is to assess con-
tinence outcomes by age in a single-surgeon series of robot-assisted radical
prostatectomies (RARP).
Method: A prospectively maintained database of men undergoing RARP be-
tween 2005 and 2015 was used to obtain data relating to disease character-
istics and continence outcomes, which were analysed stratified by age. Social
continence was defined as the patient-reported use of 0 or 1 pad per day.
Comparison across age groups was undertaken by the chi-squared test, with
trends analysed by linear regression, with statistical significance set at P <
0.05.
Results: Over the study period, 744 men were treated, of whom 644 who had
at least 12 months follow-up were analyzed. The 89 men aged over 70 years
had a higher median PSA (6.8 ng/mL vs 5.5 ng/mL), proportion of T3 tumors
(37 [42%] vs 169 [30%]) and Gleason primary 4 or higher (46 [52%] vs 179
[32%]), all P < 0.05. The social continence rate showed a steady decline with
increasing age (P < 0.001), being 90% versus 98% for patients over or under
70 respectively (P < 0.001), with the corresponding intervention rate being
4.5% versus 1.6%.
Conclusions: Continence outcomes among older men undergoing RARPwere
worse compared to younger men, but still appear acceptable in the context
of treating higher-risk PC. These results will be useful in counselling older
patients with PC when deciding on treatment modality.
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SODIUM FLOURIDE (NAF) PET/CT RESPONSE ASSESSMENT IN A
PROSPECTIVE PILOT STUDY OF OLIGOMETASTASES FROM
PROSTATE CANCER TREATED WITH STEREOTACTIC ABLATIVE
RADIOSURGERY (POPSTAR)
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Purpose: The POPSTAR study enrolled patients who had their primary
prostate cancer controlled with a presentation of one to three oligometas-
tases. This interim analysis is on patients with bone only oligometastates un-
dergoing NaF PET/CT for response assessment.
Methods: Patients received a 20 Gy single fraction of SABR and were fol-
lowed for at least 12 months. Time-to-event outcomes were calculated us-
ing Kaplan–Meier methods. NaF PET/CT was performed at baseline and
6 months post-SABR.
Results: Twenty patients with 34 bone only oligometastases were enrolled,
with a mean age of 72 years and median follow-up was 18 months. Primary
Gleason score was 4 in one, 6 in one, 7 in nine, 8 in eight, and 9 in one pa-
tient. There was one bone lesion in 11 patients (55%); two in four (20%)
patients and three in five patients (25%). There were no grade 3 or 4 adverse
events. Most common grade 1/2 toxicities were: fatigue (7), nausea (4), diar-
rhea (3), and radiation dermatitis (2). There were no deaths, with 1/34 treated
metastases progressing locally at 9 months, resulting in local progression free
survival of 95% (95% CI, 87–100) at 12 months. Distant progression free
survival after SABR was 95% (95% CI, 8–100) at 3 months; 85% (95% CI,
71–100) at 6 months; 65% (95% CI, 47–90) at 9 months and 65% (95%
CI, 47–90) at 12 months. On NaF PET/CT, the mean (±SD) SUVmax was 40
(±27) at baseline and 21 (±14) at 6 months. At 6-month PET/CT, there was
no difference in the mean change () Hounsfield units (HU) of treated lesions
demonstrating complete response (n = 4, HU = 124%) versus partial re-
sponse (n = 23,HU = 100%) versus stable disease (n = 7,HU = 103%),
one-way ANOVA P = 0.364.
Conclusion: Single fraction SABR is well tolerated and themajority of patients
do not progress within 12months of treatment. Persistent osteoblastic activity
with reduced intensity on PET associated with progressive sclerosis on CT is
consistent with a healing response.
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METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:
EXPERIENCE IN THE WAIKATO REGION WITH 2-WEEKLY VERSUS
3-WEEKLY DOCETAXEL
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Introduction: The TAX327 trial established the efficacy of 3-weekly docetaxel
chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).1
The PROSTY trial demonstrated improved time-to-treatment failure and bet-
ter tolerance with 2-weekly docetaxel chemotherapy.2 We present the local
experience with both regimes in the Waikato region, New Zealand.
Methods: This is a retrospective review of all mCRPC patients treated
with docetaxel chemotherapy in the Waikato region from January 2011 to
December 2015. Docetaxel was administered in either 2-weekly cycles (50
mg/m2) or 3-weekly cycles (75 mg/m2) with prednisone 5 mg twice daily.
Patient baseline characteristics, previous and subsequent treatment records,
treatment-related toxicities and cancer-specific outcomes (50% PSA decline,
progression-free survival [PFS], and median overall survival [OS]) were
recorded.
Results: Thirty-three patients were treated with docetaxel chemotherapy
over this period; 21 patients in the 2-weekly group and 12 patients in the
3-weekly group with a median age of 67 and 66 years, respectively. Base-
line characteristics were largely similar between groups. The median num-
ber of doses was ten in the 2-weekly group and six in the 3-weekly group.
Compared to the 3-weekly group, the 2-weekly group had a 50% PSA de-
cline of 52% versus 50% (P = 1.0), median PFS of 4.9 months versus
3.7 months (P = 0.6), and median OS of 13.6 months versus 12.8 months
(P = 0.9).
The febrile neutropenia rate was 5% in the 2-weekly group and 8% in the
3-weekly group. The incidence of any grade peripheral neuropathy was 57%
in the 2-weekly group and 17% in the 3-weekly group.
C© 2016 The Authors. Asia-Pacific Journal of Clinical Oncology Asia-Pac J Clin Oncol 2016; 12(Suppl. 3): 34–43
C© 2016 Wiley Publishing Asia Pty Ltd
Poster Abstracts - Prostate 43
Conclusion: In our study, the PSA response was similar between groups with
an improvement in cancer outcomes in the 2-weekly group but given the small
number of patients, this did not reach statistical significance. The rate of pe-
ripheral neuropathy was interestingly higher in our study than in the PROSTY
trial.
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